© 2021 MJH Life Sciences and Drug Topics. All rights reserved.
© 2021 MJH Life Sciences™ and Drug Topics. All rights reserved.
Women with recurrent ovarian cancer will now have a new therapy option. Gemcitabine (Gemzar, Lilly) has been approved for use in combination with carboplatin for advanced ovarian cancer that has relapsed at least six months after initial therapy.